Ligand id: 8714

Name: dectrekumab

No information available.
Summary of Clinical Use
Dectrekumab (QBX258) reached Phase II clinical trial as a potential biologic therapy for several immune conditions, including idiopathic pulmonary fibrosis (IPF), asthma, eosinophilic esophagitis [2] (proof of principle study NCT01022970), Crohn's disease, keloids and allergic rhinitis. As of May 2017, there are no active dectrekumab studies.
Mechanism Of Action and Pharmacodynamic Effects
Treatment with dectrekumab therapy has been shown to modulate a set of human genes indicative of a TH2-driven mechanism of action in eosinophilic esophagitis [2]. Such results suggest that other TH2-driven diseases may be amenable to the same therapeutic approach.